Work Here?
Overview
Novo Holdings manages the assets and wealth of the Novo Nordisk Foundation and holds stakes in Novo Nordisk A/S and Novozymes A/S. It runs a diversified investment portfolio across stocks, bonds, real estate, infrastructure and private equity, with a long-term return view. It also acts as a major life sciences investor through Seeds, Venture, Principal and Planetary Health Investments to back life science companies at all stages. Its goal is to grow and safeguard the Foundation’s wealth while advancing life sciences and planetary health through its investments, leveraging scale, a long horizon, and direct stakes in leading firms.
About Novo Holdings
Industries
Venture Capital
Energy
Biotechnology
Healthcare
Company Size
201-500
Company Stage
N/A
Total Funding
$18.3B
Headquarters
Gentofte Municipality, Denmark
Founded
1999
Get referred to Novo Holdings
See people who can refer or advise you
Simplify's Take
What believers are saying
- Danone completed Kate Farms acquisition on 1 July 2025, validating Novo's underwriting.
- Novo Holdings announced ForYou Medical investment on 10 September 2026, expanding wound-care manufacturing exposure.
- Benchmark Genetics completion on 31 March 2025 adds sustainable food-production genetics capabilities.
What critics are saying
- Novonesis was fined 284.5 million TL by Turkey on 23 October 2025.
- Benchmark Genetics integration in Bergen creates execution risk across aquaculture genetics operations.
- Novo Holdings' fortunes remain tightly tied to Novo Nordisk and Novonesis performance.
What makes Novo Holdings unique
- Novo Holdings controls Novo Nordisk and Novonesis, giving unmatched Nordic healthcare access.
- It backs life sciences and sustainability, including Benchmark Genetics on 31 March 2025.
- Its portfolio exits like Kate Farms sold to Danone show disciplined long-term capital recycling.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$18.3B
Above
Industry Average
Funded Over
0 Rounds
Benefits
Flexible Work Hours
Company News
Jul 27, 2026: QuantumCell, a Danish biotech firm which uses quantum technology for CNS drug development, has recently secured DKK 117.5m in fresh capital. The funding round included participation from existing investors Novo Holdings, Lundbeckfonden and Forbion, and also marked the entry of EIFO into the startup's ownership group. The capital raise is the third since QuantumCell's founding in summer 2025, and will enable the continuation of operations. The firm recently bought the rights to NeuroRestore, a drug development platform focused on Alzheimer's and other CNS diseases, from Swedish pharmaceutical company AlzeCure Pharma for a total price of up to USD 2.2bn.
Clasp Therapeutics, a biotechnology company bringing unparalleled precision to immuno-oncology using next-generation T cell engagers (TCEs), launched today w...
Asian Startups raised capital in order to expand and move into more successful. Here is this week’s Top 10 Asian Startups Funding Roundup.
Expedition Therapeutics has closed an oversubscribed $115 million series B funding round to advance its lead DPP1 inhibitor into phase 2 trials for chronic obstructive pulmonary disease (COPD). The financing attracted a roster of prominent investors. The company is developing a DPP1 inhibitor, a drug class that targets a specific enzyme involved in inflammatory diseases. The series B proceeds will support clinical development of Expedition's lead candidate as it progresses through mid-stage trials. Expedition is backed by Sanofi, though the pharmaceutical giant's participation in this particular funding round was not specified in the available information.
Latest Press Releases from Claris Bio.
Novo Holdings is Hiring for 1 Jobs on Simplify!
Find jobs on Simplify and start your career today
About Novo Holdings
Industries
Venture Capital
Energy
Biotechnology
Healthcare
Company Size
201-500
Company Stage
N/A
Total Funding
$18.3B
Headquarters
Gentofte Municipality, Denmark
Founded
1999
Novo Holdings is Hiring for 1 Jobs on Simplify!
Find jobs on Simplify and start your career today